drugset / Trial / NCT02072057
Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.
Phase 2
Terminated
8 enrolled
Kantonsspital Aarau
Clinical Trial Unit, University Hospital Basel, Switzerland · collabNovartis · collabUniversity Hospital, Basel, Switzerland · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to investigate the effects and safety of Ruxolitinib, a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) inhibitor for the treatment of tumor-associated cachexia in chronic wasting diseases.
Timeline
- Start
- 2014-04-20
- Primary completion
- 2018-11-30
- Completion
- 2018-11-30
Outcome
Outcome not reported
Stopped (Enrollment): “Poor recruiting”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | — | Oral |
Indications
No indication recorded.